Screening for chronic kidney disease in communitypharmacy: Crierfac project
- 1Cardiovascular working group, Spanish Society of Community Pharmacy, Madrid, Spain
Abstract
Introduction: Chronic kidney disease (CKD) is underdiagnosed in most countries. One reason for this is that it often presents without symptoms, so patients only seek medical attention when the disease is already advanced. Community pharmacies, due to their widespread reach and accessibility to healthcare throughout the region, can be suitable centers to complement screening efforts at primary care centers.
Objectives: To evaluate the outcomes of CKD screening in community pharmacies through creatinine measurement and glomerular filtration rate (GFR) estimation in patients meeting specific risk criteria.
Methods: Multicenter observational study. People who entered participating pharmacies for any reason and met the inclusion criterion of not having a CKD diagnosis were invited to participate in the study. Pharmacist conducted a point-of-care blood creatinine test, and the GFR was calculated using the CKD–EPI formula. Those with a positive CKD indicator (<45 ml/min/1.73 m2) were referred to their general practitioner (GP) for evaluation. People with a GFR>60 ml/min/1.73 m2 were not considered to have CKD. Those with a GFR between 45 and 60 ml/min/1.73 m2 were asked to return for reassessment 1 month later. All the data were recorded by the pharmacist.
Results: One hundred and forty-one community pharmacies from 40 provinces of Spain enrolled 2116 patients. In the first analysis, 1428 (67.5%) were negative, 165 (7.8%) were positive, and 523 (24.7%) needed a second analysis. In the second analysis, 164 (7.8%) were negative, 243 (11.5%) were positive, and 116 (5.5%) did not reattend. In summary, by intention to treat, 1592 (75.2%) were negative and 408 (19.3%) tested positive and were referred to their GP.
Conclusions: The results of CKD detection in community pharmacies are in line with screening in other healthcare settings, confirming they could be a reliable resource in future population-screening strategies
Key messages: • Chronic kidney disease (CKD) is underdiagnosed in most countries so it’s neccessesary to develop new points to screen patients.
• Community pharmacies, due to their widespread reach and accessibility to healthcare throughout the region, can be suitable centers to complement screening efforts at primary care centers.
Related
- Vitamin D screening and targeted supplementation delays liver fibrosis in patients with chronic liver disease: A prospective randomized controlled trial
- Two-Step Sequential Screening for Frailty in Patients With Chronic Liver Disease: A Triage Efficiency Study of Liver Frailty Index Components.
- Improving obstructive sleep apnea screening in patients with atrial fibrillation (SLEEP-AF project)
- Healthcare access, cervical cancer screening, and urogenital health among masculine-presenting people assigned female at birth in Thailand: The HAFFU Project
- Facilitating HPV DNA test-based screening for cervical cancer in public health settings of India: learnings from the Amethi project
BibTeX
@article{velasco2026screening,
title = {{Screening for chronic kidney disease in communitypharmacy: Crierfac project}},
author = {EJ Satue de Velasco},
journal = {The European Journal of Public Health},
year = {2026},
month = oct,
doi = {10.1093/eurpub/ckag169.857},
url = {https://doi.org/10.1093/eurpub/ckag169.857},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Screening for chronic kidney disease in communitypharmacy: Crierfac project
AU - EJ Satue de Velasco
PY - 2026
DA - 2026/10/01
JO - The European Journal of Public Health
DO - 10.1093/eurpub/ckag169.857
UR - https://doi.org/10.1093/eurpub/ckag169.857
AB - Introduction: Chronic kidney disease (CKD) is underdiagnosed in most countries. One reason for this is that it often presents without symptoms, so patients only seek medical attention when the disease is already advanced. Community pharmacies, due to their widespread reach and accessibility to healthcare throughout the region, can be suitable centers to complement screening efforts at primary care centers. Objectives: To evaluate the outcomes of CKD screening in community pharmacies through creatinine measurement and glomerular filtration rate (GFR) estimation in patients meeting specific risk criteria. Methods: Multicenter observational study. People who entered participating pharmacies for any reason and met the inclusion criterion of not having a CKD diagnosis were invited to participate in the study. Pharmacist conducted a point-of-care blood creatinine test, and the GFR was calculated using the CKD–EPI formula. Those with a positive CKD indicator (<45 ml/min/1.73 m2) were referred to their general practitioner (GP) for evaluation. People with a GFR>60 ml/min/1.73 m2 were not considered to have CKD. Those with a GFR between 45 and 60 ml/min/1.73 m2 were asked to return for reassessment 1 month later. All the data were recorded by the pharmacist. Results: One hundred and forty-one community pharmacies from 40 provinces of Spain enrolled 2116 patients. In the first analysis, 1428 (67.5%) were negative, 165 (7.8%) were positive, and 523 (24.7%) needed a second analysis. In the second analysis, 164 (7.8%) were negative, 243 (11.5%) were positive, and 116 (5.5%) did not reattend. In summary, by intention to treat, 1592 (75.2%) were negative and 408 (19.3%) tested positive and were referred to their GP. Conclusions: The results of CKD detection in community pharmacies are in line with screening in other healthcare settings, confirming they could be a reliable resource in future population-screening strategies Key messages: • Chronic kidney disease (CKD) is underdiagnosed in most countries so it’s neccessesary to develop new points to screen patients. • Community pharmacies, due to their widespread reach and accessibility to healthcare throughout the region, can be suitable centers to complement screening efforts at primary care centers.
SN - 1101-1262
SN - 1464-360X
ER -